Zoetis Inc
NYSE: ZTS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Zoetis Inc (ZTS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98.00M | $254.00M | $497.00M | $454.00M | $681.00M | $626.00M | $664.00M | $713.00M | $1.35B | $1.79B | $1.79B | $2.13B | $2.21B | $1.91B | $2.35B | $2.95B | $2.90B |
| Capital expenditures | $135.00M | $124.00M | $135.00M | $126.00M | $184.00M | $195.00M | $224.00M | $216.00M | $224.00M | $338.00M | $460.00M | $453.00M | $477.00M | $586.00M | $732.00M | $655.00M | $621.00M |
| Depreciation | $124.00M | $185.00M | $205.00M | $200.00M | $209.00M | $204.00M | $199.00M | $240.00M | $242.00M | $308.00M | $412.00M | $441.00M | $448.00M | $465.00M | $491.00M | $497.00M | $487.00M |
| Stock-based comp | $15.00M | $16.00M | $19.00M | $28.00M | $43.00M | $32.00M | $43.00M | $37.00M | $44.00M | $53.00M | $67.00M | $59.00M | $58.00M | $62.00M | $60.00M | $74.00M | $83.00M |
| Free cash flow | $-37.00M | $130.00M | $362.00M | $328.00M | $497.00M | $431.00M | $440.00M | $497.00M | $1.12B | $1.45B | $1.33B | $1.67B | $1.74B | $1.33B | $1.62B | $2.30B | $2.28B |
| Investing cash flow | $-1.82B | $-9.00M | $-449.00M | $-135.00M | $-179.00M | $-187.00M | $-1.11B | $-214.00M | $-270.00M | $-2.26B | $-504.00M | $-572.00M | $-458.00M | $-883.00M | $-777.00M | $-315.00M | $-748.00M |
| Financing cash flow | $1.82B | $-277.00M | $-30.00M | $-78.00M | $-200.00M | $-154.00M | $755.00M | $-903.00M | $-251.00M | $533.00M | $-951.00M | $123.00M | $-1.86B | $-904.00M | $-3.11B | $-2.66B | $-1.87B |
| Dividends paid | $101.00M | $207.00M | $416.00M | $63.00M | $98.00M | $146.00M | $168.00M | $188.00M | $206.00M | $243.00M | $314.00M | $380.00M | $474.00M | $611.00M | $692.00M | $786.00M | $889.00M |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $293.00M | $272.00M | $272.00M | $-427.00M | $837.00M | $38.00M | $332.00M | $1.68B | $-107.00M | $125.00M | — | — | — |
Frequently asked questions
What is Zoetis Inc's revenue?
Zoetis Inc's trailing twelve-month revenue is $9.53B, and consensus projects about $12.34B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is ZTS?
In its most recent fiscal year, ZTS ran a gross margin of 70.49%, an operating margin of 38.00%, and a net margin of 28.23%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does ZTS generate?
ZTS produced $2.28B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ZTS's balance sheet healthy?
ZTS holds $2.31B in cash and equivalents against $9.04B in long-term debt, on $3.33B of shareholder equity. That debt is best read against the cash flow the business throws off each year.